Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886821 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
NCT00886821 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 114 participants.
The verdict
NCT00886821, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
Interventions
- BIOLOGICAL CVX-096
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00886821
The ClinicalTrials.gov registry entry for NCT00886821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVX-096 is the first listed.
NCT00886821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00886821 about?
NCT00886821 is a clinical study titled "A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics". The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
What is the current status of trial NCT00886821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2008-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00886821?
The interventions under investigation include: CVX-096 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00886821?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.